A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.

Phase 1

M.D. Anderson Cancer Center

Regeneron Pharmaceuticals

Cemiplimab